OncoSil Medical Moves to BSI Management for CE Mark

  • Nov 19, 2019 AEDT
  • Team Kalkine

Medical device company, OncoSil Medical Ltd (ASX: OSL) has provided updated on its CE Marking review after a meeting with BSI Management.

  • Post Market Surveillance (PMS) Plan and Post Market Clinical Follow-up (PMCF) programme were discussed in the meeting.
  • Based on the discussion, OSL has decided to formally submit the OncoSilTM device application and PMS, PMCF plans for review.
  • It expects to finalise commercialisation plans in an anticipation of CE mark approval in the coming months.

By 1:23 PM AEST, OSL was trading at $0.185, down by 11.9% relative to the previous close.


All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK